Wave Life Sciences, Inc.

WVE ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-204.4M $-97.0M $-57.5M $-161.8M $-122.2M $-149.9M $-193.6M $-146.7M
Depreciation & Amortization — — — — — — — —
Depreciation $3.4M $3.9M $5.0M $6.6M $7.5M $8.1M $7.6M $5.6M
Amortization — — — — — — — —
Stock-Based Compensation — — — — — — — —
Net Cash from Operating Activities $-187.5M $-151.0M $-19.4M $-127.8M $-89.0M $-116.0M $-188.2M $-22.9M
Investing Activities
Capital Expenditures $718.0K $938.0K $1.1M $1.4M $560.0K $1.3M $3.9M $9.9M
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities $-718.0K $-938.0K $-1.1M $-1.3M $-560.0K $-1.3M $-3.9M $-9.9M
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $488.2M $253.9M $132.5M $67.2M $55.8M $154.5M $164.4M $65.1M
Net Change in Cash $300.0M $101.8M $111.9M $-62.1M $-33.9M $37.3M $-27.6M $32.3M
Free Cash Flow $-188.2M $-152.0M $-20.5M $-129.1M $-89.6M $-117.3M $-192.1M $-32.8M
← Newer Page 1 of 2 Older →